Atherosclerosis
Volume 211, Issue 1 , Pages 237-241 , July 2010

Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine

  • Dan-yan Xu

      Affiliations

    • Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • Corresponding Author InformationCorresponding authors at: 139 Middle Renming Road, Department of Cardiology, Internal Medicine, Second Xiangya Hospital, Changsha, Hunan 410011, PR China. Tel.: +86 731 5292100; fax: +86 731 4895989.
    • ,
  • Jun Shu

      Affiliations

    • Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • ,
  • Quan-yue Huang

      Affiliations

    • Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • ,
  • Binaya Wasti

      Affiliations

    • Department of Respiratory Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • ,
  • Chen Chen

      Affiliations

    • Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • ,
  • Ling Liu

      Affiliations

    • Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • ,
  • Shui-ping Zhao

      Affiliations

    • Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • Corresponding Author InformationCorresponding authors at: 139 Middle Renming Road, Department of Cardiology, Internal Medicine, Second Xiangya Hospital, Changsha, Hunan 410011, PR China. Tel.: +86 731 5292100; fax: +86 731 4895989.

Received 28 August 2009 ,Revised 27 January 2010 ,Accepted 27 January 2010.

References 

  1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;363:801–809
  2. Li JJ, Fang CH. Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis. Med Hypotheses. 2004;63:100–102
  3. Tracy RP. Inflammation in cardiovascular disease: cart, horse or both?. Circulation. 1998;97:2000–2002
  4. Li JJ. Inflammation: an important mechanism for different clinical entities of coronary artery diseases. Chin Med J. 2005;118:1817–1826
  5. Kwak BR, Mach F. Statins inhibit leukocyte recruitment new evidence for their anti-inflammatory properties. Arterioscler Thromb Vasc Biol. 2001;21:1256–1258
  6. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States 2002. Adv Data. 2004;343:1–19
  7. Yang Weng-ji, Fu Xiao-jie. Comparing the lipid lowing effects between zhibituo and atorvastain. Zhong Guo Xian Dai Yi Yao Ke Ji. 2003;2:2–4
  8. Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115(February (6)):700–707[Epub 2007 February 5]
  9. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  10. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–2445
  11. Li Shen-zi, Li Ping-tu. Comparing the effects of simvastatin with zhibituo on lipoprotein abnormality. Fu Jian Yi Yao Za Zhi. 2006;28:139–140
  12. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–2497
  13. Becker DJ, Gordon RY, Morris PB, et al. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc. 2008;83:758–764
  14. Ma J, Li Y, Ye Q, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem. 2000;48(11):5220–5225
  15. Patrick L, Uzick M. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Altern Med Rev. 2001;6(3):248–271
  16. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  17. Baldassarre D, Porta B, Camera M, et al. Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis. 2009;19(September (7)):481–490
  18. Peason TA, Mensah GA, Alexander RW, et al. Marder of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from centers for Disease control and prevention and the American Heart Association. Circulation. 2003;107:499–511
  19. Zhao SP, Xu DY. Oxidized lipoprotein(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thromb Res. 2000;100:501–510
  20. Haider N, Hartung D, Fujimoto S, et al. Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis. J Nucl Cardiol. 2009;16:753–762
  21. Chang WT, Dao J, Shao ZH. Hawthorn: potential roles in cardiovascular disease. Am J Chin Med. 2005;33(1):1–10
  22. Qian Jia-Jun. Serial studies of the effects of Alisma L. on atherosclerosis(1)—progression of the research of Alisma L. J Beijing Univ Trad Chin Med. 1991;14:42
  23. Li XY, Weng HY, Cai D. Influence of Shenlinbaizhu Powder on 30 patients with metabolic syndrome. CJGMCM, 2009, 24(March(3)):496–7.
  24. Li JJ, Lu ZL, Kou WR, et al. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol. 2009;49:947–956

☆ This work was supported by 2008 National Nature Scientific Funding of China (No. 30770856), 2008 Program for New Century Excellent Talents in University (NCET-08-0566) and Grant of Institute of Metabolism and Endocrine of Central South University of 2008 (DY-2008-02-04).

PII: S0021-9150(10)00092-4

doi: 10.1016/j.atherosclerosis.2010.01.044

Atherosclerosis
Volume 211, Issue 1 , Pages 237-241 , July 2010

Article Tools